Search Medical Condition
Please enter condition
Please choose location

Hepatoblastoma Clinical Trials

A listing of Hepatoblastoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (128) clinical trials

Phlebotomy to Prevent Blood Loss in Major Hepatic Resections

Major liver resection is associated with significant intraoperative blood loss. Blood loss in elective liver surgery is a key determinant of perioperative morbidity and mortality, as well as possibly long-term oncologic outcome. Whole blood phlebotomy is a simple intervention, whose aim is to decrease the central venous pressure yielding a ...

Phase N/A

Mobilization of Mesenchymal Stem Cells During Liver Transplantation

Mesenchymal stem cells (MSCs) are a known immune modulator with significant immunosuppressive effects. MSCs have emerged as a promising frontier in human clinical trials. MSCs have been shown to be non-immunogenic making them capable of transplantation across allogeneic barrier. These qualities make MSCs an ideal candidate to study if they ...

Phase N/A

Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience

Background Hepatoblastoma (HB) is the most common malignant liver tumor in children, with an incidence of 0.7 to 1 per million children <15 years of age. Till 1970s, surgery was the primary modality of treatment of HB. Unfortunately, up to 60% of the patients present in an unresectable stage. Later, ...

Phase N/A

Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)

In the currently ongoing retrospective aspect of the study, we will obtain pathologic tumor explant specimens from the tumor explant population from 8/1/1994 to 12/31/2005. We will prepare 5-10 slides from each tumor explant block and measure HIF-1 using immunohistochemical staining. We will also be performing a retrospective chart review ...

Phase N/A

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere

The purpose of this protocol is to provide supervised access at this institution to TheraSphere® treatment for a heterogeneous population of patients with unresectable primary liver tumors, with the liver being the only dominant site of disease. Based on experience gained in previous studies and well-established interventional radiology techniques, this ...

Phase N/A

Microwave Ablation of Resectable Liver Tumors

Minimally invasive surgical alternatives are becoming more attractive for the treatment of malignancy.The goal is to reduce morbidity and mortality and increase the ability to treat patients in the outpatient setting. Image-guided ablation is becoming an attractive alternative because of its relative low cost, its ability to provide large regions ...

Phase N/A

TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma

This protocol provides TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. Patients with hepatocellular carcinoma will be evaluated for eligibility for this treatment with the following: physical examination, medical history, blood tests requiring approximately 2 tablespoons of blood, EKG, CT or MR of chest to ...

Phase N/A

HAI Via Interventionally Implanted Port Catheter Systems

Inclusion criteria: - histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation. - non-resectable disease or hepatic resection or ablation in between the past 8 weeks. - measurable disease (at least before hepatic resection) - Karnofsky performance status => 70%, or ECOG status 0-2 - >18 years of age - life ...

Phase

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP), which misses 40-60% of patients with liver cancer because it lacks sufficient specificity and sensitivity. The purpose of this study ...

Phase N/A

Biomarkers and Radiation Side Effects in Patients Undergoing Radiation Therapy for Gastrointestinal Cancer

OBJECTIVES: Primary - Determine if tumor-specific DNA mutations and aberrant DNA methylation can be detected in the serum, urine, or stool at the time of diagnosis in patients undergoing radiotherapy for gastrointestinal malignancies. - Determine if changes in mutational status at follow up are associated with disease persistence, recurrence, or ...

Phase N/A